ATTCs – Talk Bio

Actionable Insights Powered by AI

HUTCHMED Divests 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million to Focus on Core Oncology Pipeline

4 months ago talkbio0Tagged antibody-targeted therapy, ATTCs, HUTCHMED, Immunostimulating conjugate (antigen), Oncology Pipeline, profitability, Shanghai, Strategic Focus

HUTCHMED, Shanghai Hutchison Pharmaceuticals, divestment, oncology pipeline, antibody-targeted therapy conjugates (ATTCs), strategic focus, profitability.